Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28415502 | 0.77 | KDM4E (0.37) | NPC1RAB9AKDM4EALDH1A1HTR3A | |
| SCHEMBL12502511 | 0.77 | FAAH (0.46) | MAPK1NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL28158746 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1HTR3AHRH4MAPT | |
| SCHEMBL6916239 | 0.75 | KDM4E (0.36) | NPC1RAB9AKDM4EALDH1A1HTR3A | |
| SCHEMBL7333314 | 0.74 | SIGMAR1 (0.47) | HTR3AHRH4MAPTMEN1KMT2A | |
| SCHEMBL983301 | 0.72 | KDM4E (0.38) | RAB9AKDM4EALDH1A1SMN1; SMN2HTR3A | |
| SCHEMBL25301116 | 0.70 | HCRTR1 (0.39) | MAPK1NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL9934866 | 0.69 | KDM4E (0.42) | KDM4EALDH1A1HTR3AHRH4MAPT | |
| SCHEMBL882940 | 0.69 | KDM4E (0.42) | KDM4EALDH1A1HTR3AHRH4MAPT | |
| SCHEMBL6664087 | 0.68 | MAPK1 (0.60) | MAPK1NPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150757-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-11 | — | — | US | disclosed |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9522905-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-20 | — | — | US | disclosed |
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9255080-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-09 | — | — | US | disclosed |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-10 | — | — | US | disclosed |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-20 | — | — | US | disclosed |
| US-8623884-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| US-8623872-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| EP-1763523-B1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-20 | — | — | EP | disclosed |
| WO-2001010860-A2 | QUINAZOLINONE AND AZAQUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-15 | — | — | WO | disclosed |
| EP-0184258-B1 | NOVEL DERIVATIVES OF HYDROXY- OR AMINO-SUBSTITUTED (PIPERIDINYLALKYL)QUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-05-06 | — | — | EP | disclosed |
| US-4665075-A | ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-05-12 | — | — | US | disclosed |
| US-4665075-A | ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-05-12 | — | — | US | disclosed |
| US-4665075-A | ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-05-12 | — | — | US | disclosed |
| EP-0184258-A2 | Novel derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
| EP-0184258-A2 | Novel derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
| EP-0184258-A2 | Novel derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
| US-4522945-A | SEROTONINE ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-11 | — | — | US | disclosed |
| EP-0013612-A2 | (Piperidinylalkyl)quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | MAPK1 1548/4885NPC1 2322/4885RAB9A 3782/4885 |
| US-10150757-B2 | Quinazolinone derivatives as PARP inhibitors | PARP1, PARP3, PARP2 | MAPK1 1962/4885NPC1 3239/4885RAB9A 2216/4885 |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | MAPK1 1962/4885NPC1 3239/4885RAB9A 2216/4885 |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | MAPK1 1962/4885NPC1 3239/4885RAB9A 2216/4885 |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | MAPK1 1548/4885NPC1 2322/4885RAB9A 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.